+Compare
EBS
Stock ticker: NYSE
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
178.22M

EBS Emergent Biosolutions Forecast, Technical & Fundamental Analysis

a manufacturer of biopharmaceutical products

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for EBS with price predictions
08:00 PM EDT Sep 21, 2023

EBS in -10.69% downward trend, sliding for three consecutive days on September 22, 2023

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where EBS declined for three days, in of 305 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 11, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on EBS as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for EBS turned negative on September 21, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

The Aroon Indicator for EBS entered a downward trend on September 20, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EBS advanced for three days, in of 286 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.186) is normal, around the industry mean (85.167). P/E Ratio (17.730) is within average values for comparable stocks, (58.499). EBS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.390). EBS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.027). P/S Ratio (0.161) is also within normal values, averaging (61.283).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EBS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Intra-Cellular Therapies (NASDAQ:ITCI), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.58B. The market cap for tickers in the group ranges from 246 to 81.31B. ZTS holds the highest valuation in this group at 81.31B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 3%. For the same Industry, the average monthly price growth was 17%, and the average quarterly price growth was 10%. CHHE experienced the highest price growth at 1,900%, while INNPF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -55%. For the same stocks of the Industry, the average monthly volume growth was 87% and the average quarterly volume growth was 73%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 58
SMR Rating: 85
Profit Risk Rating: 92
Seasonality Score: -11 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

EBS is expected to report earnings to fall 99.69% to 0 cents per share on November 02

Emergent Biosolutions EBS Stock Earnings Reports
Q3'23
Est.
$0.00
Q2'23
Missed
by $0.43
Q1'23
Missed
by $1.93
Q4'22
Missed
by $0.35
Q3'22
Missed
by $1.21
The last earnings report on August 08 showed earnings per share of -105 cents, missing the estimate of -62 cents. With 1.50M shares outstanding, the current market capitalization sits at 178.22M.
A.I. Advisor
published General Information

General Information

a manufacturer of biopharmaceutical products

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Professional Drive
Phone
+1 240 631-3200
Employees
2500
Web
https://www.emergentbiosolutions.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SEKRX16.310.18
+1.12%
DWS Emerging Markets Equity R6
LVOAX16.260.01
+0.06%
Lord Abbett Value Opportunities A
IVJAX8.70N/A
N/A
Delaware Ivy International Small Cap A
AAAVX10.79-0.03
-0.28%
DWS RREEF Real Assets R6
EQNVX18.60-0.10
-0.53%
MFS Equity Income R6

EBS and

Correlation & Price change

A.I.dvisor indicates that over the last year, EBS has been loosely correlated with ELAN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-5.23%
ELAN - EBS
44%
Loosely correlated
-0.71%
SUPN - EBS
39%
Loosely correlated
+1.95%
SIGA - EBS
39%
Loosely correlated
+0.64%
DVAX - EBS
38%
Loosely correlated
-0.66%
EVO - EBS
36%
Loosely correlated
+1.37%
More

Groups containing EBS

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-5.23%
vaccines
(undefined stocks)
39%
Loosely correlated
-0.07%
biotechnology
(undefined stocks)
34%
Loosely correlated
-0.81%
drugs
(undefined stocks)
30%
Poorly correlated
-0.89%
biopharmaceuticals
(undefined stocks)
28%
Poorly correlated
-0.37%
Pharmaceuticals
(undefined stocks)
7%
Poorly correlated
-0.04%
More